ImmuneRegen Begins Homspera Studies For Swine Flu

ImmuneRegen BioSciences (ImmuneRegen), a wholly-owned subsidiary of IR Biosciences, has initiated a study utilising the highly pathogenic H5N1-Clade 2 virus to test the efficacy of its lead anti-influenza drug – Homspera.

Reportedly, the study is a continuation of studies previously sponsored by ImmuneRegen testing the efficacy of Homspera in treating the novel H1N1 Influenza strain, currently considered a pandemic by the WHO.

ImmuneRegen has reported that Homspera will be tested for efficacy against highly lethal H5N1 Avian Influenza. The company said that the testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.

Moreover, ImmuneRegen is further evaluating the previously demonstrated vaccine adjuvant effect of Homspera in combination with a vaccine for H5N1. The study is being sponsored by a strategic partner of ImmuneRegen and is utilising a novel H5N1 antigen and delivery technology.

Arizona-based ImmuneRegen BioSciences is a development-stage biotechnology company focused on the research, development and licensing of Homspera and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant.